Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study
Authors:
- Daniele SantiniDSDaniele Santini
- Bruno VincenziBVBruno Vincenzi
- Francesco M GuidaFGFrancesco M Guida
- Marco ImperatoriMIMarco Imperatori
- Gaia SchiavonGSGaia Schiavon
- Olga VendittiOVOlga Venditti
- Anna M FrezzaAFAnna M Frezza
- Pierpaolo BertiPBPierpaolo Berti
- Giuseppe ToniniGTGiuseppe Tonini
- 1 October 2012
- journal article
- clinical trial
- Published by Elsevier in The Lancet Oncology
- Vol. 13 (10) , 1020-1024
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- More on Aprepitant for Erlotinib-Induced PruritusNew England Journal of Medicine, 2011
- Aprepitant for Erlotinib-Induced PruritusNew England Journal of Medicine, 2010
- Preliminary evidence for a role of mast cells in epidermal growth factor receptor inhibitor–induced pruritusJournal of the American Academy of Dermatology, 2010
- Targeting the Neurokinin Receptor 1 with Aprepitant: A Novel Antipruritic StrategyPLOS ONE, 2010
- Aprepitant as an Antipruritic Agent?New England Journal of Medicine, 2009
- Neuropeptides and their receptors in psoriatic skin in relation to pruritusBritish Journal of Dermatology, 2007
- Epidermal Growth Factor Receptor Inhibitor–Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical ManagementThe Oncologist, 2007
- Description and management of cutaneous side effects during cetuximab or erlotinib treatments: A prospective study of 30 patientsJournal of the American Academy of Dermatology, 2006
- Neuroanatomy and neurophysiology of itchDermatologic Therapy, 2005
- Topical anti-itch therapyDermatologic Therapy, 2005